Comments on COVID-19 and AL Amyloidosis, the Missing Links.
作者信息
Jain Ankur
机构信息
Department of Haematology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
出版信息
Am J Med. 2022 Jun;135(6):e137-e138. doi: 10.1016/j.amjmed.2022.02.011.
Abstract
摘要
相似文献
1
Comments on COVID-19 and AL Amyloidosis, the Missing Links.关于新型冠状病毒肺炎与轻链型淀粉样变性：缺失的环节之评论
Am J Med. 2022 Jun;135(6):e137-e138. doi: 10.1016/j.amjmed.2022.02.011.
2
Perioral skin thickening revealing AL amyloidosis.
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):e703-e705. doi: 10.1111/jdv.18157. Epub 2022 Apr 30.
3
Mucocutaneous Xanthodermatosis as Initial Presentation of Immunoglobulin Light Chain Amyloidosis.皮肤黏膜黄瘤病作为免疫球蛋白轻链淀粉样变性的初始表现
Am J Med. 2022 Jun;135(6):724-727. doi: 10.1016/j.amjmed.2021.12.011. Epub 2022 Jan 23.
4
How well does liver span as part of the consensus criteria for liver involvement in AL amyloidosis perform?作为AL淀粉样变性肝脏受累共识标准一部分的肝径，其表现如何？
Amyloid. 2023 Dec;30(4):437-439. doi: 10.1080/13506129.2023.2222878. Epub 2023 Jun 15.
5
Systemic Light Chain Amyloidosis. Reply.系统性轻链淀粉样变性。回复。
N Engl J Med. 2024 Sep 26;391(12):1165-1166. doi: 10.1056/NEJMc2409196.
6
Intraoral hemorrhagic bullae as the first sign of immunoglobulin light chain amyloidosis.口腔内出血性大疱作为免疫球蛋白轻链淀粉样变性的首发症状
CMAJ. 2024 May 26;196(20):E705. doi: 10.1503/cmaj.240119.
7
Silver-positive kidney AL amyloidosis.
J Nephrol. 2024 May;37(4):1175-1176. doi: 10.1007/s40620-023-01827-1. Epub 2024 Jan 22.
8
A Case of Disseminated Systemic Light-Chain Amyloidosis with Coagulopathy.
Am J Med. 2023 Mar;136(3):e51. doi: 10.1016/j.amjmed.2022.06.013.
9
Systemic amyloidosis presented with leonine facies.
QJM. 2024 Apr 12;117(4):287-288. doi: 10.1093/qjmed/hcad267.
10
Reversing the poor prognosis of primary amyloid light‑chain amyloidosis with cardiac involvement.
Pol Arch Intern Med. 2022 Apr 28;132(4). doi: 10.20452/pamw.16197. Epub 2022 Jan 25.
引用本文的文献
1
COVID-19 Infection and Vaccination and Its Relation to Amyloidosis: What Do We Know Currently?新型冠状病毒肺炎感染与疫苗接种及其与淀粉样变性的关系：我们目前了解多少？
Vaccines (Basel). 2023 Jun 24;11(7):1139. doi: 10.3390/vaccines11071139.
本文引用的文献
1
COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury.COVID-19 与轻链淀粉样变性，雪上加霜。
Am J Med. 2022 Apr;135 Suppl 1:S49-S52. doi: 10.1016/j.amjmed.2022.01.005. Epub 2022 Jan 23.
2
BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.BNT162b2信使核糖核酸新冠疫苗加强针可使先前两剂疫苗接种无反应的B细胞非霍奇金淋巴瘤患者发生血清转化。
Br J Haematol. 2022 Mar;196(6):1329-1333. doi: 10.1111/bjh.18029. Epub 2022 Jan 25.
3
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
4
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
5
Potential 'significance' of monoclonal gammopathy of 'undetermined significance' during COVID-19 pandemic.新型冠状病毒肺炎大流行期间意义未明的单克隆丙种球蛋白病的潜在“意义”
Blood Cells Mol Dis. 2020 Nov;85:102481. doi: 10.1016/j.bcmd.2020.102481. Epub 2020 Jul 24.
6
Pathophysiology and management of monoclonal gammopathy of renal significance.肾脏相关意义单克隆免疫球蛋白病的病理生理学和治疗方法。
Blood Adv. 2019 Aug 13;3(15):2409-2423. doi: 10.1182/bloodadvances.2019031914.
Zotero 插件